Quarterly ResultMay 11, 2026, 04:51 PM
Sanara MedTech Q1 Net Revenue +19% to $27.8M; Net Profit $0.04/Share
AI Summary
Sanara MedTech Inc. reported strong financial results for the first quarter ended March 31, 2026, with net revenue increasing 19% to $27.8 million. The company achieved GAAP net profitability from continuing operations of $0.4 million, or $0.04 per diluted share, a significant improvement from a net loss in the prior year. This performance reflects the company's sharpened focus on the surgical market and enhanced financial model. Sanara MedTech reaffirmed its full-year 2026 net revenue guidance of $116 million to $121 million, representing 13% to 17% growth.
Key Highlights
- Net revenue increased 19% to $27.8 million in Q1 2026 from $23.4 million in Q1 2025.
- Net income from continuing operations was $0.4 million, or $0.04 per diluted share, in Q1 2026.
- Gross profit rose to $25.9 million, representing 93% of net revenue, up from 92% in Q1 2025.
- Adjusted EBITDA increased 58% to $4.3 million in Q1 2026 from $2.7 million in Q1 2025.
- Sales of soft tissue repair products grew 21% to $24.9 million in Q1 2026.
- Cash stood at $13.6 million and long-term debt at $46.2 million as of March 31, 2026.
- Reaffirmed full-year 2026 net revenue guidance of $116M-$121M (13%-17% growth).
- Projected Q2 2026 net revenue of $28.5M-$29.5M, representing 10%-14% growth.